# Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation

> **NCT06793410** · PHASE2 · RECRUITING · sponsor: **Vastra Gotaland Region** · enrollment: 100 (estimated)

## Conditions studied

- Recipients of Allogeneic Stem Cell Transplantation
- HPV (Human Papillomavirus)-Associated
- Acute Myeloid Leukaemia
- Myelodysplastic Syndrome
- Diffuse Large B Cell Lymphoma (DLBCL)

## Interventions

- **BIOLOGICAL:** Early start post-transplant vaccination with Gardasil 9®
- **BIOLOGICAL:** Late post-transplant vaccination with Gardasil 9®

## Key facts

- **NCT ID:** NCT06793410
- **Lead sponsor:** Vastra Gotaland Region
- **Sponsor class:** OTHER_GOV
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-05-12
- **Primary completion:** 2029-10-31
- **Final completion:** 2029-10-31
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2025-06-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06793410

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06793410, "Vaccination Against Human Papillomavirus (HPV) After Allogeneic Stem Cell Transplantation". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT06793410. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*